@article{AOL4451,
author = {Julia Dai and Timothy Almazan and Youn Kim and Michael Khodadoust},
title = {Pembrolizumab in systemic and cutaneous T-cell lymphoma},
journal = {Annals of Lymphoma},
volume = {2},
number = {4},
year = {2018},
keywords = {},
abstract = {Suppression of antitumor immunity through programmed death-1 (PD-1) interaction between lymphoma cells and the tumor environment plays a key role in lymphoma cell survival. Pharmacologic disruption of the PD-1 axis using antibodies against PD-1 or its ligands has demonstrated significant antitumor activity in solid tumors with similar evidence emerging in hematologic malignancies. Pembrolizumab, an immune checkpoint inhibitor of the PD-1/programmed death-ligand 1 (PD-L1) axis, has significant clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS). The promising findings of pembrolizumab in MF and SS warrant further investigation of PD-1 blockade in the treatment of systemic and cutaneous T-cell lymphomas.},
issn = {2616-2695}, url = {https://aol.amegroups.org/article/view/4451}
}